Trump Proposes Tariffs on Imports of Patented Drugs

On Thursday, President Donald Trump announced that certain patented drugs and related ingredients imported into the United States could face tariffs of up to 100%. He framed this decision as a matter of national security while aiming to boost domestic drug manufacturing.

The proposed system would create different tariff rates for drug manufacturers. Companies that have domestic production plans approved by the Commerce Department would see a lower tariff of 20%, whereas some companies with specific pricing and manufacturing agreements with the government could even be exempt from tariffs for a limited time.

A senior official in the administration referred to this policy as essentially imposing a “100% tax” on medications produced abroad. President Trump highlighted the significant volume of imported drugs and essential ingredients, stating that they “are being imported into the United States in such quantities and under conditions that they threaten to compromise the national security of the United States.”

The plan has already encountered legal challenges as it moves through the courts. Under this new framework, imports listed in a specific Annex would generally incur a 100% customs duty unless a lower tariff condition is met.

As part of the rationale behind this approach, the administration argues that the U.S. relies too heavily on foreign drug production. Around 53% of patented medicines sold in the U.S. come from overseas, while only 15% of the active ingredients are produced domestically.

In a bid to encourage domestic manufacturing, companies that receive approvals for U.S. production plans will be subject to a 20% tariff, which is set to rise to 100% by 2030. Officials assert this structure is an incentive for companies to relocate their operations back to the United States.

The proposal also makes allowances for specific allies, offering 15% tariffs for products from Japan, the European Union, South Korea, and Switzerland, while products from the United Kingdom may face a 10% tariff—or potentially none under future agreements.

Importantly, this initiative does not currently apply to generic drugs or U.S.-manufactured drugs. The broader plan ties into the TrumpRx initiative, including the recently launched TrumpRx.gov platform aimed at allowing Americans to purchase some expensive brand-name drugs at reduced prices through favorable pricing agreements with manufacturers.

According to the announcement, the tariffs are slated to come into effect on July 31, 2026, for some companies, with others following on September 29, 2026. President Trump invoked Section 232 of the Trade Expansion Act of 1962, which permits the president to restrict imports viewed as national security threats.